Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
NCT07428707Phase 1Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Mar 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Immune cell composition of lymph nodes estimated by deconvolution of bulk RNA sequencing. Started Mar 2026; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07428707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428707.